Efficacy and Safety of a Standardized Diuretic Protocol in Acute Heart Failure: A Historical Control Study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250127001

Enrollment

160

Registered

2025-01-27

Start date

2025-05-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure patient Heart failure Diuretic treatment Heart failure management

Interventions

A standardized diuretic protocol in managing patient with acute heart failure.

Active Comparator Drug

Standardized diuretic regimen

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adults aged more than 20 years old, admitted to general internal medicine ward of Maharaj Nakorn Chiangmai Hospital between January 1, 2025, to December 31, 2026. 2. Patients diagnosed with acute heart failure, characterized with congestive symptom such as dyspnea, fatigue, orthopnea, paroxysmal nocturnal dyspnea (PND), and ankle swelling. 3. Patients with clinical evidence of congestion, such as peripheral edema, elevated jugular venous pressure, or signs of pulmonary congestion (e.g., rales on auscultation). 4. Patients able to provide informed consent or have a legally authorized representative provide consent.

Exclusion criteria

Exclusion criteria: 1. Patients with significant hypotension (systolic blood pressure less than 90 mmHg) at the time of admission. 2. Patients with shock requiring vasopressors or inotropic agents for hemodynamic support. 3. Patients diagnosed with acute ST-segment elevation myocardial infarction. 4. Patients diagnosed with severe mitral stenosis, severe aortic stenosis, severe aortic regurgitation, or pericardial disease. 5. Patients requiring renal replacement therapy or ultrafiltration.

Design outcomes

Primary

Measure	Time frame
Length of hospital stay At discharge day in index hospitalization The days of hospital stay	—

Secondary

Measure	Time frame
Duration of intravenous furosemide During index hospitalization Length of intravenous furosemide administration,Incidence of heart failure rehospitalization 30 days Number of heart failure rehospitalization after index event,Hypotension During index hospitalization Blood presure measurement	—

Countries

Thailand

Contacts

Public ContactPanadda Thipdeth

Faculty of Medicine, Chiang Mai University

panadda3173@gmail.com053936793

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026